PDCD1 and cancer: It works through the targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1), known as immune checkpoints, which inhibit immune response [3,4] and can be employed by cancer cells to escape attacks from the immune system.